10x Genomics (TXG) Receivables (2018 - 2026)

10x Genomics' Receivables history runs 9 years deep, the most recent figure standing at $56.1 million for Q1 2026.

• In Q1 2026, Receivables rose 6.83% year-over-year to $56.1 million; the TTM figure through Mar 2026 stood at $56.1 million (up 6.83% YoY), while the FY2025 annual figure was $82.5 million, down 6.75% from the prior year.
• Receivables came in at $56.1 million for Q1 2026 at 10x Genomics, down from $82.5 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $119.1 million in Q2 2025 to a low of $52.5 million in Q1 2025.
• A 5-year average of $87.4 million and a median of $87.7 million in 2023 frame the typical range for Receivables.
• Across the five-year window, Receivables soared 33.3% in 2022 and plunged 42.45% in 2025, its largest moves.
• 10x Genomics' Receivables stood at $104.2 million in 2022, then rose by 10.19% to $114.8 million in 2023, then dropped by 22.96% to $88.5 million in 2024, then fell by 6.75% to $82.5 million in 2025, then tumbled by 31.95% to $56.1 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $56.1 million, $82.5 million, and $96.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison